Exploring CYP17 Gene Polymorphism as a Predictive Marker in Iraqi Women with Polycystic Ovary Syndrome and Its Association with Hormonal Dysregulation
CYP17A1 Polymorphism in Iraqi women with PCOS
DOI:
https://doi.org/10.31661/gmj.vi.3746Keywords:
Polycystic Ovary Syndrome; CYP17 Gene; Polymorphism; Anti-Müllerian HormoneAbstract
Background: Although most women of reproductive age diagnosed with polycystic ovary syndrome (PCOS) represent a common disorder with significant long-term health implications. Investigations on the CYP17A1 gene, which plays a pivotal role in androgen biogenesis, explored its potential role as a predictive marker for the risk of PCOS. This research was conducted to evaluate the association of CYP17A1 polymorphism (rs743572 variant) with susceptibility to polycystic ovarian syndrome (PCOS) among the Iraqi population. Materials and Methods: We executed a case-control study consisting of 66 PCOS patients and 74 controls. Restriction Fragment Length Polymorphism (RFLP) was used to detect the genotypes. Results: The TT genotype of CYP17A1 was significantly associated with an increased risk of PCOS, with an approximately fourfold higher odds of developing PCOS versus the CC genotype. No significant increase in risk was seen for the CT genotype. The TT polymorphism of CYP17A1 (rs743572) was significantly associated with PCOS (adjusted OR=3.97, P=0.03), while the CT variant showed a non-significant trend, after adjusting for age and BMI. Conclusion: The current study, by providing further evidence for the association between CYP17A1 genetic polymorphisms and PCOS in multi-ethnic populations, has important implications for the management of this complex disorder, indicating the potential use of genotyping in assessing the genetic risk of the disorder in different ethnic groups.
References
Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. European journal of obstetrics & gynecology and reproductive biology: X. 2019 Jul 1;3:100060.
https://doi.org/10.1016/j.eurox.2019.100060
Akhtar MK, Kelly SL, Kaderbhai MA. Cytochrome b5 modulation of 17α hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. Journal of Endocrinology. 2005 Nov 1;187(2):267-74.
https://doi.org/10.1677/joe.1.06375
Albedairy I H, Aljawad M F, AL-Shammari J M, Alshareefi A F. The CYP17A1 single-nucleotide polymorphism rs743572 in . Iraqi polycystic ovary syndrome patients. 2024;1:8.
https://doi.org/10.21203/rs.3.rs-3925107/v1
Al-Lami HB, Al-Tu'ma FJ, Al-Safi WG. Association between anti-Müllerian hormone and other biomarkers with ovarian function in polycystic ovarian syndrome of Iraqi women. Journal of Contemporary Medical Sciences. 2020 Jul 1;6(4): .
https://doi.org/10.22317/jcms.v6i4.824
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2005 Apr 1;90(4):1929-35.
https://doi.org/10.1210/jc.2004-1045
Ashraf S, Rasool SU, Nabi M, Ganie MA, Jabeen F, Rashid F, Amin S. CYP17 gene polymorphic sequence variation is associated with hyperandrogenism in Kashmiri women with polycystic ovarian syndrome. Gynecological Endocrinology. 2021 Mar 4;37(3):230-4.
https://doi.org/10.1080/09513590.2020.1770724
Azziz R. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. The Journal of Clinical Endocrinology & Metabolism. 2006 Mar 1;91(3):781-5.
https://doi.org/10.1210/jc.2005-2153
Bao X, Ding H, Xu Y, Cui G, He Y, Yu X, Wang DW. Prevalence of common mutations in the CYP17A1 gene in Chinese Han population. Clinica chimica acta. 2011 Jun 11;412(13-14):1240-3.
https://doi.org/10.1016/j.cca.2011.03.019
Boldis BV, Grünberger I, Cederström A, Björk J, Nilsson A, Helgertz J. Comorbidities in women with polycystic ovary syndrome: a sibling study. BMC Women's Health. 2024 Apr 5;24(1):221.
https://doi.org/10.1186/s12905-024-03028-9
Burns K, Mullin BH, Moolhuijsen LM, Laisk T, Tyrmi JS, Cui J, Actkins KE, Louwers YV, Estonian Biobank Research Team Metspalu Andres Milani Lili Esko Tõnu Nelis Mari Hudjashov Georgi, Davis LK, Dudbridge F. Body mass index stratified meta-analysis of genome-wide association studies of polycystic ovary syndrome in women of European ancestry. BMC genomics. 2024 Feb 26;25(1):208.
https://doi.org/10.1186/s12864-024-09990-w
Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clinical endocrinology. 1993 Jun;38(6):653-8.
https://doi.org/10.1111/j.1365-2265.1993.tb02150.x
Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human molecular genetics. 1994 Oct 1;3(10):1873-6.
https://doi.org/10.1093/hmg/3.10.1873
Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Human reproduction. 2006 Sep 1;21(9):2223-7.
https://doi.org/10.1093/humrep/del165
Chaudhary H, Patel J, Jain NK, Joshi R. The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis. Journal of ovarian research. 2021 Sep 26;14(1):125.
https://doi.org/10.1186/s13048-021-00879-w
Chua A K, Azziz R, Goodarzi M O. Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage. MHR: Basic science of reproductive medicine. (2012);18(6): 320-324.
https://doi.org/10.1093/molehr/gas002
Chen Y, Pei J. Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis. Breast Cancer Research and Treatment. 2010 Jul;122:471-81.
https://doi.org/10.1007/s10549-009-0690-9
Cong L, Fu Q, Gao T. CYP17A1 rs743572 polymorphism might contribute to endometriosis susceptibility: evidences from a case-control study. Medicine. 2018 Jul 1;97(28):e11415.
https://doi.org/10.1097/MD.0000000000011415
de Medeiros SF, Barbosa JS, Yamamoto MM. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. Journal of Obstetrics and Gynaecology Research. 2015 Feb;41(2):254-63.
https://doi.org/10.1111/jog.12524
Douma Z, Lautier C, Haydar S, Mahjoub T, Grigorescu F. Portability of GWAS results between ethnic populations: genetic markers for polycystic ovary syndrome (PCOS) in mediterranean area. Acta Endocrinologica (Bucharest). 2019 Jul;15(3):364.
https://doi.org/10.4183/aeb.2019.364
Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reproductive Biology and Endocrinology. 2015 Dec;13:1-0.
https://doi.org/10.1186/s12958-015-0134-9
Gill L, Coborn JE, Hoovler AR, Sherif K. Polycystic ovary syndrome and obesity: a cross-sectional survey of patients and obstetricians/gynecologists. Journal of Women's Health. 2023 Jun 1;32(6):723-31.
https://doi.org/10.1089/jwh.2022.0471
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019 Mar 1;92:108-20.
https://doi.org/10.1016/j.metabol.2018.11.002
Goodarzi MO, Carmina E, Azziz R. Dhea, dheas and pcos. The Journal of steroid biochemistry and molecular biology. 2015 Jan 1;145:213-25.
https://doi.org/10.1016/j.jsbmb.2014.06.003
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature reviews endocrinology. 2011 Apr;7(4):219-31.
https://doi.org/10.1038/nrendo.2010.217
Güngör ND, Güngör K, Celik N, Önal M, Madenli AA. Impact of body mass index and vitamin D on serum AMH levels and antral follicle count in PCOS. Eur Rev Med Pharmacol Sci. 2023 Jan 1;27:179-87.
Hassan B F. Measuring the concentration of some hormones in patients sera of polycystic ovaries. Baghdad Science Journal. (2010); 7(4): 1384-1388.
https://doi.org/10.21123/bsj.7.4.1384-1388
Heidarzadehpilehrood R, Pirhoushiaran M, Abdollahzadeh R, Binti Osman M, Sakinah M, Nordin N, Abdul Hamid H. A review on CYP11A1, CYP17A1, and CYP19A1 polymorphism studies: candidate susceptibility genes for polycystic ovary syndrome (PCOS) and infertility. Genes. 2022 Feb 5;13(2):302.
https://doi.org/10.3390/genes13020302
Hendriks ML, Brouwer J, Hompes PG, Homburg R, Lambalk CB. LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo/amenorrhoea. Reproductive biomedicine online. 2008 Jan 1;16(6):765-71.
https://doi.org/10.1016/S1472-6483(10)60140-X
Hoyos LR, Visser JA, McLuskey A, Chazenbalk GD, Grogan TR, Dumesic DA. Loss of anti-Müllerian hormone (AMH) immunoactivity due to a homozygous AMH gene variant rs10417628 in a woman with classical polycystic ovary syndrome (PCOS). Human Reproduction. 2020 Oct;35(10):2294-302.-Jabr, I. M., & Al-Hakeim, H. K. (2015). Relation of Antimullarian Hormone with other Hormones in Women with Polycystic Ovary Syndrome. Al-Kufa University Journal for Biology, 7(1)
https://doi.org/10.1093/humrep/deaa199
Jahromi MS, Tehrani FR, Noroozzadeh M, Zarkesh M, Ghasemi A, Zadeh-Vakili A. Elevated expression of steroidogenesis pathway genes; CYP17, GATA6 and StAR in prenatally androgenized rats. Gene. 2016 Nov 15;593(1):167-71.
https://doi.org/10.1016/j.gene.2016.07.067
Jakubowicz DJ, Nestler JE. 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. The Journal of Clinical Endocrinology & Metabolism. 1997 Feb 1;82(2):556-60.
https://doi.org/10.1210/jcem.82.2.3753
Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. The Journal of Clinical Endocrinology & Metabolism. 2004 Jan 1;89(1):318-23.
https://doi.org/10.1210/jc.2003-030932
Legro R S. Obesity and PCOS: implications for diagnosis and treatment In Seminars in reproductive medicine. Thieme Medical Publishers. 2012;30(6):496-506.
https://doi.org/10.1055/s-0032-1328878
Li L, Gu ZP, Bo QM, Wang D, Yang XS, Cai GH. Association of CYP17A1 gene-34T/C polymorphism with polycystic ovary syndrome in Han Chinese population. Gynecological Endocrinology. 2015 Jan 2;31(1):40-3.
https://doi.org/10.3109/09513590.2014.947948
Liu X, Xu M, Qian M, Yang L. CYP17 T/C (rs74357) gene polymorphism contributes to polycystic ovary syndrome susceptibility: evidence from a meta-analysis. Endocrine Connections. 2021 Dec 1;10(12):R305-16.
https://doi.org/10.1530/EC-21-0327
Liu XY, Yang YJ, Tang CL, Wang K, Chen JJ, Teng XM, Ruan YC, Yang JZ. Elevation of antimüllerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin. Fertility and sterility. 2019 Jan 1;111(1):157-67.
https://doi.org/10.1016/j.fertnstert.2018.09.022
Lu L, Luo J, Deng J, Huang C, Li C. Polycystic ovary syndrome is associated with a higher risk of premalignant and malignant endometrial polyps in premenopausal women: a retrospective study in a tertiary teaching hospital. BMC Women's Health. 2023 Mar 24;23(1):127.
https://doi.org/10.1186/s12905-023-02269-4
Ma R, Zou Y, Wang W, Zheng Q, Feng Y, Dong H, Tan Z, Zeng X, Zhao Y, Deng Y, Wang Y. Obesity management in polycystic ovary syndrome: disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China. BMC Endocrine Disorders. 2021 Dec;21:1-0.
https://doi.org/10.1186/s12902-021-00848-w
Malini NA, George KR. Evaluation of different ranges of LH: FSH ratios in polycystic ovarian syndrome (PCOS)-Clinical based case control study. General and comparative endocrinology. 2018 May 1;260:51-7.-Munawar Lone, N., Babar, S., Sultan, S., Malik, S., Nazeer, K., & Riaz, S. (2021). Association of the CYP17 and CYP19 gene polymorphisms in women with polycystic ovary syndrome from Punjab, Pakistan. Gynecological Endocrinology, 37(5), 456-461.
https://doi.org/10.1080/09513590.2020.1822803
Nelson VL, Legro RS, Strauss III JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Molecular endocrinology. 1999 Jun 1;13(6):946-57.
https://doi.org/10.1210/mend.13.6.0311
Nestler JE, Jakubowicz DJ, Falcon de Vargas A, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. The Journal of Clinical Endocrinology & Metabolism. 1998 Jun 1;83(6):2001-5.
https://doi.org/10.1210/jcem.83.6.4886
Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, Brown K, Simpson ER, Mason HD. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertility and sterility. 2011 Nov 1;96(5):1246-51.
https://doi.org/10.1016/j.fertnstert.2011.08.015
Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. (2006) ; 91(3): 941-945.
https://doi.org/10.1210/jc.2005-2076
Rahimi Z. The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) variants in polycystic ovary syndrome: A case-control study. International Journal of Reproductive BioMedicine. 2019 May 29;17(3):201.
https://doi.org/10.18502/ijrm.v17i3.4519
Saddick S Y. Identifying genes associated with the development of human polycystic ovary syndrome. Saudi Journal of Biological Sciences. (2020); 27(5): 1271-1279.
https://doi.org/10.1016/j.sjbs.2020.01.012
Teixeira J, Fynn-Thompson E, Payne AH, Donahoe PK. Mullerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology. 1999 Oct 1;140(10):4732-8.
https://doi.org/10.1210/endo.140.10.7075
Wawrzkiewicz-Jałowiecka A, Kowalczyk K, Trybek P, Jarosz T, Radosz P, Setlak M, Madej P. In search of new therapeutics-molecular aspects of the PCOS pathophysiology: genetics, hormones, metabolism and beyond. International Journal of Molecular Sciences. 2020 Sep 25;21(19):7054.
https://doi.org/10.3390/ijms21197054
Wickenheisser JK, Biegler JM, Nelson-DeGrave VL, Legro RS, Strauss III JF, McAllister JM. Cholesterol side-chain cleavage gene expression in theca cells: augmented transcriptional regulation and mRNA stability in polycystic ovary syndrome. PloS one. 2012 Nov 14;7(11):e48963.
https://doi.org/10.1371/journal.pone.0048963
Xing C, Zhao H, Zhang J, He B. The association of CYP17A1, CYP19A1, and SHBG gene polymorphisms in polycystic ovary syndrome susceptibility: a systematic review and meta-analysis. Frontiers in Physiology. 2022 May 9;13:741285.
https://doi.org/10.3389/fphys.2022.741285
Zhao Y, Xu Y, Wang X, Xu L, Chen J, Gao C, Wu C, Pan D, Zhang Q, Zhou J, Chen R. Body mass index and polycystic ovary syndrome: a 2-sample bidirectional Mendelian randomization study. The Journal of Clinical Endocrinology & Metabolism. 2020 Jun;105(6):1778-84.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
